guide Low Evidence

Weight-Loss Peptides in 2026: What Human Trials Actually Show

Compare approved weight-management medicines with investigational peptides using study-specific trial endpoints, current regulatory status, and clear limits on cross-trial claims.

PepCodex Research Team
6 min read
#weight-loss #glp-1 #peptides #semaglutide #tirzepatide #retatrutide #ranking #2026

“Best” is not one trial percentage. In September 2026, semaglutide, tirzepatide and liraglutide have FDA-approved weight-management products, while CagriSema and retatrutide remain investigational. Their studies differ in participants, follow-up, endpoints and how missing data are handled. A larger percentage from one trial cannot establish that its treatment is better than another treatment tested in a different trial. This page compares the evidence, not which medicine a person should use.

The page-level evidence grade is low for a single cross-drug ranking. That does not downgrade the large randomized trials for individual approved products; it marks the uncertainty in turning different trials and sponsor announcements into one ordering.

What can be compared directly?

The published SURMOUNT-5 trial directly randomized adults with obesity without type 2 diabetes to tirzepatide or semaglutide for 72 weeks. Its least-squares mean weight changes were −20.2% and −13.7%, respectively. This supports a tirzepatide advantage for weight change in that trial and population. It does not establish a universal choice across people with diabetes, cardiovascular disease, different contraindications, or different treatment goals. Both groups used a maximum tolerated dose; the result should not be recast as one fixed-dose comparison.

The pivotal placebo-controlled trials answer different questions. STEP 1 studied semaglutide in 1,961 adults without diabetes for 68 weeks and reported mean weight change of −14.9% versus −2.4% with placebo. SURMOUNT-1 studied 2,539 adults without diabetes for 72 weeks; the trial’s treatment-regimen estimand reported −20.9% in its highest-dose tirzepatide arm versus −3.1% with placebo. SCALE Obesity and Prediabetes studied liraglutide for 56 weeks in 3,731 adults without diabetes and reported mean losses of 8.4 versus 2.8 kg with placebo using last-observation-carried-forward imputation. These are within-trial results with different methods and units, not a valid three-way head-to-head ranking.

Weight change is also not the only outcome. In SELECT, semaglutide reduced major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity without diabetes; FDA approved that specific Wegovy indication. Liraglutide’s LEADER trial demonstrated a cardiovascular benefit in type 2 diabetes with high cardiovascular risk, not a Saxenda obesity-outcomes trial. Tirzepatide now has a published SURPASS-CVOT in type 2 diabetes and established atherosclerotic cardiovascular disease: it met noninferiority against active comparator dulaglutide for major events, but not superiority. These populations, comparators and regulatory indications are distinct.

What remains investigational?

CagriSema combines semaglutide with the amylin analogue cagrilintide. Published REDEFINE 1 randomized 3,417 adults without diabetes; its treatment-policy estimate was −20.4% versus −3.0% with placebo at 68 weeks. The combination is not FDA-approved as of this review; Novo Nordisk submitted an application in December 2025. Its later sponsor-reported, open-label REDEFINE 4 compared CagriSema with tirzepatide over 84 weeks and did not meet the prespecified noninferiority endpoint for weight loss. That finding belongs beside, not underneath, the placebo-controlled result. It prevents a confident claim that CagriSema outperforms tirzepatide.

Retatrutide activates GIP, GLP-1 and glucagon receptors and is not FDA-approved. A published Phase 2 obesity trial reported substantial 48-week weight reduction in its studied groups. Lilly has since reported Phase 3 topline results, including −28.3% at 80 weeks in one TRIUMPH-1 arm. The TRIUMPH-1 announcement is a sponsor report, not the peer-reviewed Phase 3 paper, and its efficacy estimand, trial population and follow-up are not matched to STEP 1, SURMOUNT-1 or REDEFINE 1. It cannot be used to declare retatrutide the most effective obesity medicine.

Why are AOD-9604 and MK-677 outside this comparison?

AOD-9604 was investigated for obesity, so “no human trials” would be wrong. An FDA review of the underlying development records reports that the larger randomized oral obesity study did not find a significant weight-loss advantage over placebo and that development for this indication ended. The FDA also notes limits in the publicly available trial reporting. That historical program does not establish benefit for other formulations or routes.

MK-677 (ibutamoren/LUM-201) is a small molecule, not a peptide. In a 65-person randomized study of healthy older adults, fat-free mass increased, but there was no significant reduction in visceral or total fat; fasting glucose rose and insulin sensitivity fell. The study did not detect a strength or function benefit, but its size and duration were insufficient to rule one out. A registered Phase 2 study plans to test LUM-201 added to semaglutide in older adults with obesity and mild functional impairment. It was not yet recruiting in the archived September 2026 record and has no outcome results; its main question is physical function, not a demonstrated weight-loss benefit. FDA says ibutamoren is unapproved.

Other growth-hormone secretagogues and BPC-157 are sometimes promoted alongside weight-loss peptides, but the trials above do not test them as substitutes for approved obesity medicines. A proposed mechanism is not a patient-level weight-loss outcome.

The useful distinction in 2026 is approved indication versus investigational development, direct comparison versus separate trials, and published result versus sponsor readout. The evidence here is educational and cannot determine an individual’s treatment; clinical decisions require a qualified healthcare professional.

Sources & Citations

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.